Literature DB >> 10102622

Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity.

C Blankenship1, J G Naglich, J M Whaley, B Seizinger, N Kley.   

Abstract

The VHL tumor suppressor gene has previously been reported to encode a protein of 213 amino acid residues. Here we report the identification of a second major VHL gene product with an apparent molecular weight of 18 kD, pVHL18, which appears to arise from alternate translation initiation at a second AUG codon (codon 54) within the VHL open reading frame. In vitro and in vivo studies indicate that the internal codon in the VHL mRNA is necessary and sufficient for production of pVHL18. pVHL18 can bind to elongin B, elongin C, and Hs-CUL2. When reintroduced into renal carcinoma cells that lack a wild-type VHL allele, pVHL18 suppresses basal levels of VEGF expression, restores hypoxia-inducibility of VEGF expression, and inhibits tumor formation in nude mice. These data strongly support the existence of two distinct VHL gene products in VHL tumor suppression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10102622     DOI: 10.1038/sj.onc.1202473

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  38 in total

Review 1.  HIF hydroxylation and the mammalian oxygen-sensing pathway.

Authors:  Michal Safran; William G Kaelin
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

2.  A novel VHLα isoform inhibits Warburg effect via modulation of PKM splicing.

Authors:  Yanbin Liu; Haixia Yang; Lin Li; She Chen; Feifei Zuo; Liang Chen
Journal:  Tumour Biol       Date:  2016-07-29

3.  Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products.

Authors:  A R Schoenfeld; E J Davidowitz; R D Burk
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

4.  Endocytic function of von Hippel-Lindau tumor suppressor protein regulates surface localization of fibroblast growth factor receptor 1 and cell motility.

Authors:  Tien Hsu; Yair Adereth; Nurgun Kose; Vincent Dammai
Journal:  J Biol Chem       Date:  2006-02-27       Impact factor: 5.157

5.  Influence of the RNA-binding protein HuR in pVHL-regulated p53 expression in renal carcinoma cells.

Authors:  Stefanie Galbán; Jennifer L Martindale; Krystyna Mazan-Mamczarz; Isabel López de Silanes; Jinshui Fan; Wengong Wang; Jochen Decker; Myriam Gorospe
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

Review 6.  Promising systemic therapy for renal cell carcinoma.

Authors:  Matthew M Cooney; Scot C Remick; Nicholas J Vogelzang
Journal:  Curr Treat Options Oncol       Date:  2005-09

7.  Oxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor protein.

Authors:  Isabelle Groulx; Stephen Lee
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

Review 8.  VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment.

Authors:  W Kimryn Rathmell; Shufen Chen
Journal:  Expert Rev Anticancer Ther       Date:  2008-01       Impact factor: 4.512

9.  Differences in regulation of tight junctions and cell morphology between VHL mutations from disease subtypes.

Authors:  Valentina Bangiyeva; Ava Rosenbloom; Ashlynn E Alexander; Bella Isanova; Timothy Popko; Alan R Schoenfeld
Journal:  BMC Cancer       Date:  2009-07-14       Impact factor: 4.430

10.  Molecular targeted therapy in advanced renal cell carcinoma: A review of its recent past and a glimpse into the near future.

Authors:  John S P Yuen
Journal:  Indian J Urol       Date:  2009 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.